Endocrinology, metabolism & nutrition Cardiovascular & respiratory systems
Author, co-author :
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Language :
English
Title :
Do thiazolidinediones increase the risk of congestive heart failure and cardiovascular death?
Publication date :
2008
Journal title :
Nature Clinical Practice Endocrinology and Metabolism
Home PD et al. (2007) Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 357: 28-38
Erdmann E et al. (2007) Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 30: 2773-2778
Nathan DM et al. (2008) Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: update regarding the thiazolidinediones. Diabetologia 51: 8-11
The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368: 1096-1105
Bolen S et al. (2007) Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147: 386-399
